Which genomic target regions and assay formats are recommended for IVD fungal pathogen diagnostics?

For IVD manufacturers developing molecular fungal diagnostics, the recommended genomic targets are the multicopy ribosomal RNA gene regions—specifically the internal transcribed spacers (ITS1 and ITS2) and the D1/D2 domains of the 28S rRNA gene—combined with assay formats that pair broad-range pan-fungal PCR with species-level probe hybridization, real-time PCR, or direct sequencing. These targets provide the sensitivity required for low-biomass clinical samples and the sequence variability needed to differentiate dozens of pathogenic genera, from Candida and Aspergillus to dimorphic and mucoralean molds.

A successful fungal IVD assay is built on the ribosomal RNA operon—targeting ITS1/ITS2 for maximum species resolution or 28S D1/D2 for robust genus-level identification—using broad-range amplification followed by specific probe detection or sequencing. The choice of format depends on the clinical need: broad syndromic panels, targeted pathogen detection, or resistance marker profiling.

The Core Genomic Targets for Pan-Fungal Detection

Why the Ribosomal RNA Operon is the Workhorse

The fungal ribosomal RNA gene complex provides a unique combination of highly conserved primer-binding sites and hypervariable internal sequences. This allows a single set of primers to amplify DNA from virtually all clinically relevant fungi while the amplicon itself contains sufficient polymorphism for species identification.

The most impactful feature for IVD sensitivity is the high copy number — typically 50 to 100 copies of the rDNA unit per haploid genome. In samples with extremely low fungal loads, this multicopy nature dramatically increases the probability of detection compared to a single-copy gene.

ITS1 and ITS2: The Gold Standard for Species-Level Discrimination

The internal transcribed spacers (ITS1, located between 18S and 5.8S rDNA, and ITS2, between 5.8S and 28S rDNA) are the most widely recommended targets for identifying a broad spectrum of fungi down to the species level.

These regions accumulate mutations rapidly and therefore exhibit high interspecies polymorphism while still being flanked by highly conserved sequences suitable for universal primer design. For clinical specimens dominated by human DNA, amplicons should be kept short (100–300 bp) to maximize PCR efficiency when amplifying fragmented fungal DNA.

28S D1/D2 and 18S rDNA: The Backbone for Genus-Level and Broad-Range Detection

When the diagnostic question is “is any fungus present?” or when a robust genus-level call is sufficient, the D1/D2 domains of the 28S rRNA gene and the 18S rRNA gene serve as excellent targets. These loci evolve more slowly than the ITS spacers, making them less informative for species-level distinction but more conserved across a phylum, which simplifies primer design for true pan-fungal amplification.

Many broad-range PCR protocols combine D1/D2 amplification with sequencing or species-specific probe panels, while 18S rDNA is often used as an internal amplification control or for initial pan-fungal screening.

Assay Format Selection: From Pan-Fungal Amplification to Specific Identification

Broad-Range PCR Followed by Multiplex Probe Hybridization

This format is foundational for syndromic panel development. A single pan-fungal PCR—using primers that anneal to conserved sequences flanking ITS or 28S—generates an amplicon from any pathogenic fungus present. Species identification is then achieved by hybridizing the product to a panel of fluorogenic probes designed against the variable internal sequences.

This approach enables the detection of dozens of pathogens in a single reaction well and is ideal for IVD kits intended for sterile site infections where the range of possible culprits is wide.

Broad-Range PCR with Direct Sequencing

When a target product cannot be reduced to a finite panel of probes—for example, when rare or unexpected molds are a concern—post-amplification Sanger or NGS sequencing of the ITS or D1/D2 amplicon provides the most comprehensive identification.

This format offers near-universal species-level resolution but requires a longer turnaround time and a bioinformatics pipeline. It is optimally suited for reference laboratories or as a reflex test after a pan-fungal screen.

Real-Time PCR with Organism-Specific Probes

For direct detection from primary clinical specimens—without prior culture—real-time PCR assays using highly specific probe hybridization are the format of choice.

These assays target signature sequences within the ribosomal operon (or, for select species complexes, single-copy genes) and deliver a quantitative or qualitative result directly from blood, BAL fluid, or tissue biopsies. Key examples include assays designed for Aspergillus or Pneumocystis. This format yields the fastest time-to-result and is the backbone of many on-demand molecular diagnostics.

Overcoming Key Technical Hurdles in Fungal IVD Design

Conquering the Fungal Cell Wall for Reliable Extraction

Fungal cell walls are thick, rigid structures composed of glucans and chitin, making nucleic acid release far more challenging than for bacteria or viruses. Chemical disruption agents (formic acid, trifluoroacetic acid) or mechanical bead beating must be integrated into the sample preparation protocol.

Without this step, even the best primers will fail to amplify target DNA, leading to false negatives. IVD manufacturers should pre-treat positive control materials in the same manner to validate the entire workflow.

The Imperative of Fungal-DNA-Free Reagents

A critical and often underestimated requirement is the use of polymerases and master mixes certified to be free of contaminating fungal DNA.

Many recombinant enzyme preparations contain traces of host-derived fungal nucleic acids. In a pan-fungal assay designed for high analytical sensitivity, this background can generate a false-positive signal that undermines the entire test. Manufacturer certification and in-house lot validation with negative controls are non-negotiable.

Validated Positive and Internal Controls

Robust controls are essential. Positive controls should include a defined amount of purified fungal genomic DNA representing key pathogen groups (e.g., Candida albicans, Aspergillus fumigatus). An internal control—often a conserved 18S rDNA fragment or a synthetic spiked-in sequence—must be co-amplified in every reaction to verify extraction efficiency and PCR inhibition.

Designing Assays for Specific Clinical Syndromes and Resistance

Tailoring Targets to High-Risk Syndromes

Clinical need dictates target selection. For fungal osteomyelitis and joint infections, multiplex panels must cover Candida species (especially C. albicans), Aspergillus, dimorphic fungi, and Scedosporium. For invasive fungal sinusitis in immunocompromised patients, the panel must shift to include mucoralean molds, Fusarium, and dematiaceous fungi like Bipolaris and Curvularia.

In these contexts, combining broad-range ITS amplification with syndrome-specific probe panels ensures that the most probable pathogens are rapidly identified while leaving the door open for less common organisms via sequencing.

Incorporating Antifungal Resistance Markers

Modern molecular IVDs increasingly include resistance gene targets to guide therapy directly from the positive specimen. The recommended markers are:

• ERG11 and CYP51A mutations/overexpression for azole resistance in Candida and Aspergillus.
• FKS gene hotspots for echinocandin resistance in Candida and Aspergillus fumigatus.
• Squalene epoxidase mutations for terbinafine resistance in dermatophytes.

These single-copy targets can be added as parallel real-time PCR reactions or included in a multiplex probe panel alongside the primary ribosomal identification assay.

Understanding the Trade-offs

Sensitivity vs. Specificity in Target Choice

Multicopy ribosomal targets offer exceptional sensitivity but can, in rare cases, amplify non-pathogenic environmental fungi or cross-react with closely related species if probe design is not stringent. In contrast, single-copy genes like EF1α or β-tubulin provide unequivocal species-level discrimination—essential for resolving complexes within Fusarium, Aspergillus, or Scedosporium—but their lower copy number reduces sensitivity in pauci-fungal samples. Many IVD designs use a two-tier approach: a sensitive ribosomal screen followed by a single-copy confirmatory or resistance assay.

Speed vs. Depth of Identification

Real-time PCR with specific probes delivers a result in under two hours but can only identify the organisms on the pre-defined panel. Broad-range PCR with sequencing identifies virtually any fungus but adds hours to days to the workflow. IVD developers must match the format to the clinical urgency: a rapid real-time panel for acute invasive aspergillosis suspicion, versus a broader sequencing-based kit for chronic or culture-negative infections where a rare mold is suspected.

The Contamination Risk of Pan-Fungal Assays

The very power of broad-range primers—their ability to amplify any fungal DNA—makes them exquisitely sensitive to reagent contamination. This risk forces the use of expensive fungal-DNA-free enzymes and rigorous environmental controls, increasing the cost of goods and the complexity of kit validation compared to a narrow, pathogen-specific assay.

Making the Right Choice for Your Diagnostic Goal

The optimal target and format align directly with the clinical question your IVD kit is designed to answer.

• If your primary focus is a broad-spectrum pan-fungal screen for sterile site infections: Use broad-range PCR targeting ITS2 or 28S D1/D2, followed by multiplex probe hybridization or sequencing. Prioritize multicopy loci and validate for fungal-DNA-free reagents.
• If your primary focus is rapid, targeted detection of a specific pathogen like Aspergillus or Pneumocystis directly from blood or BAL: Design a real-time PCR assay with fluorogenic probes specific to that organism’s ribosomal sequence, and keep the amplicon under 300 bp.
• If your primary focus is resolving cryptic species complexes for epidemiological precision or therapy guidance: Supplement a ribosomal screen with single-copy gene targets (EF1α, β-tubulin) via parallel PCR or targeted NGS.
• If your primary focus is building a syndrome-specific panel (e.g., fungal sinusitis, osteomyelitis): Start with a conserved core amplification (ITS) and then deploy a panel of syndrome-relevant species-specific probes for the most common causative molds and yeasts.
• If your primary focus is a comprehensive IVD that includes antifungal resistance: Add real-time or probe-based detection of ERG11/CYP51, FKS, and squalene epoxidase gene mutations to your identification workflow, using validated reference materials.

Match the genomic architecture to the clinical need, and you will deliver a diagnostic tool that is both powerfully sensitive and precisely informative.

Summary Table:

Accelerate Your Molecular Diagnostic Development with CamelBio

Designing sensitive, contamination-free molecular fungal assays requires top-tier reagents and expert technical support. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic.

From high-purity, fungal-DNA-free enzymes to robust control design and workflow optimization, our experts are here to support your product line. Contact CamelBio today to discuss your diagnostic development needs!